Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (4 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
2 selected
)
Type
Guidance (33)
Quality standard (0)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (1)
Diagnostics guidance (1)
NICE guidelines (1)
Technology appraisal guidance (33)
Apply filters
Showing 21 to 30 of 33
Sort by
Date
Title
Apply sorting
multiple myeloma
Remove multiple myeloma filter
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Lenalidomide with bortezomib and dexamethasone for untreated
multiple myeloma
(terminated appraisal)
TA603
25 September 2019
25 September 2019
Lenalidomide for the treatment of
multiple myeloma
in people who have received at least 2 prior therapies
TA171
18 June 2009
26 June 2019
Lenalidomide plus dexamethasone for
multiple myeloma
after 1 treatment with bortezomib
TA586
26 June 2019
26 June 2019
Lenalidomide plus dexamethasone for previously untreated
multiple myeloma
TA587
26 June 2019
26 June 2019
Denosumab for preventing skeletal-related events in
multiple myeloma
(terminated appraisal)
TA549
5 December 2018
5 December 2018
Bortezomib for treating
multiple myeloma
after second or subsequent relapse (terminated appraisal)
TA453
5 July 2017
5 July 2017
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA454
5 July 2017
5 July 2017
Elotuzumab for previously treated
multiple myeloma
(terminated appraisal)
TA434
22 March 2017
22 March 2017
Pomalidomide for
multiple myeloma
previously treated with lenalidomide and bortezomib
TA427
11 January 2017
11 January 2017
Panobinostat for treating
multiple myeloma
after at least 2 previous treatments
TA380
27 January 2016
27 January 2016
Previous page
1
2
Current page
3
4
Page
3
of
4
Next page
Results per page
10
25
50
All
Back to top